Clinical Trial Update: Randomized Study of Extended Treatment With Firibastat in Treatment-Resistant Hypertension (REFRESH) [Phase 3]

View source ↗

Summary

Phase 3 randomized study on extended Firibastat treatment in treatment-resistant hypertension has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Firibastat (firibastat)

Snippet

Sponsor: Quantum Genomics SA | Conditions: Hypertension (HTN) | Phase 3 | Status: TERMINATED